Ajanta Pharma Ltd
Ajanta Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue and margins.
The short version
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
From Ajanta Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Ajanta Pharma Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.4K Cr, net profit ₹267 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
Ajanta Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ajanta Pharma Ltd Q1 FY27 results?
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
What is Ajanta Pharma Ltd share price analysis?
Ajanta Pharma Ltd currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma Ltd planning capital expenditure?
The provided document is a cover letter for the written transcript of Ajanta Pharma's earnings call held on 30th July 2026.
Keep Ajanta Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.